Overall, our results demonstrate a molecular sub-cluster of colon cancer cells with low CDX2 and VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment and provide an example of translation of colon cancer classification to subgroups guided targeted therapies. Here, CDX2 is linked to colonic neoplasm.